Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study
Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning
 most often in subjects aged 20-40 years. In France, thanks to recent studies reported during
 general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3
 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy,
 the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year.

 The primary objective of this pilot study is to assess the levels of glutamate and aspartate
 (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in
 40 patients experiencing an event demyelinating central nervous system.
Inclusion Criteria:

 -  Man or woman between 18 and 60 years old.

 -  Patient with one or more type of inflammatory events of Central system suggestive of
 demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive
 myelitis)

 -  No treatment with corticosteroids for less than 1 month

 -  Need for a lumbar puncture performed in the etiologic

 -  Need a brain MRI performed within the etiologic

 -  Patient who signed informed consent

 Exclusion Criteria:

 -  Secondary progressive MS

 -  Any cons-indication for lumbar puncture

 -  Any contra-indication to MRI

 -  Minor patient or patient major under guardianship